고형암 (전체)

#LocallyAdvancedHeadandNeckSquamo#Antibody#Phase2#항체#면역항체+2

durvalumab (Imfinzi, Durvalumab + Tremelimumab + RT)

Locally Advanced Head and Neck Squamous Cell Carcinoma · Locally Advanced Head and Neck Squamous

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+4

durvalumab (Imfinzi, Durvalumab + doxorubicin + ifosfamide)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase2#항체#면역항체+2

durvalumab (Imfinzi, Durvalumab Plus Tremelimumab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

효능 ORR 37.4%임상시험 1상태 ACTIVE

#GastrointestinalNeuroendocrineCa#Antibody#Phase2#항체#면역항체+2

oxaliplatin and capecitabine (Durvalumab and Chemotherapy, Durvalumab and Chemotherapy(oxaliplatin and capecitabine))

Gastrointestinal Neuroendocrine Carcinoma · Gastrointestinal Neuroendocrine Carcinom

pembrolizumab (Keytruda, Durvalumab or Pembrolizumab)

Biliary Tract Neoplasms; Advanced Cancer · Biliary Tract Neoplasms

pembrolizumab (Keytruda, Durvalumab or Pembrolizumab + Levnatinib)

Biliary Tract Neoplasms; Advanced Cancer · Biliary Tract Neoplasms

pembrolizumab (Keytruda, Durvalumab or Pembrolizumab + SCL-3010)

Biliary Tract Neoplasms; Advanced Cancer · Biliary Tract Neoplasms

pembrolizumab (Keytruda, Durvalumab or Pembrolizumab + Venadaparib)

Biliary Tract Neoplasms; Advanced Cancer · Biliary Tract Neoplasms

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2

durvalumab (Imfinzi, Durvalumab plus Lenvatinib)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase2#항체#면역항체+2

durvalumab (Imfinzi, Durvalumab with Carboplatin/Paclitaxel)

Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma of the Head and

#LargeCellNeuroendocrineCarcinoma#Antibody#Phase2#항체#면역항체+2

durvalumab (Imfinzi, Durvalumab with etoposide and Carboplatin/Cisplatin)

Large Cell Neuroendocrine Carcinoma of the Lung · Large Cell Neuroendocrine Carcinoma of t

#HCC-HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2

durvalumab (Imfinzi, Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting)

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#B2Thymoma#CGT#Phase2#세포유전치료#CAR-T+3

EB-CAR30-NK (EB-CAR30-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#세포유전치료#CAR-T+3

EB-CAR5-NK (EB-CAR5-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#B2Thymoma#CGT#Phase2#세포유전치료#CAR-T+3

EB-CARMSLN-NK (EB-CARMSLN-NK)

B2 Thymoma; Thymic Carcinoma · B2 Thymoma

#PancreaticDuctalAdenocarcinomaPD#CGT#Phase2#세포유전치료#CAR-T+3

MSLN + MUC1 (EB-DNK101 dual-targeting CAR-NK cells, EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · Pancreatic Ductal Adenocarcinoma (PDAC)

#CLDN182#CGT#Phase2#세포유전치료#CAR-T+4

CLDN18.2 + MUC1 (EB-DNK102 dual-targeting CAR-NK cells, EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1))

Pancreatic Ductal Adenocarcinoma (PDAC); Unresectable Locally Advanced or Metastatic Disease · CLDN18.2

#CEA#CGT#Phase2#세포유전치료#CAR-T+4

EB-DUO-CAR-NK-CEA/GCC (EB-DUO-CAR-NK-CEA/GCC)

Colorectal Cancer; Metastatic Colorectal Adenocarcinoma · CEA

#AdvancedHepatocellularCarcinomaH#CGT#Phase2#세포유전치료#CAR-T+3

EB-G3B7-NK dual-target CAR-NK cells (EB-G3B7-NK dual-target CAR-NK cells)

Advanced Hepatocellular Carcinoma (HCC); Metastatic Liver Cancer · Advanced Hepatocellular Carcinoma (HCC)